Pharmacyte Biotech Inc (PMCB) 0.0308 $PMCB Phar
Post# of 273242
Posted On: 09/19/2016 5:11:25 AM
Pharmacyte Biotech Inc (PMCB) 0.0308 $PMCB
PharmaCyte's CEO Discusses Development of its Pancreatic Cancer Therapy
GlobeNewswire - Thu Sep 15, 8:15AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today addressed shareholders on the development of PharmaCyte's therapy for advanced pancreatic cancer.
PharmaCyte Biotech Reports on Progress in Its Medical Cannabis Program
GlobeNewswire - Thu Sep 01, 8:35AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today provided an update on its program for developing treatments for serious brain cancers that involve constituents of the Cannabis plant. These Cannabis-based cancer therapies, like PharmaCyte's pancreatic cancer therapy, will involve the use of its Cell-in-a-Box technology. The cancer "prodrug" that will be activated (converted to their cancer-killing forms) by the cells inside the Cell-in-a-Box capsules are constituents of the Cannabis plant known as cannabinoids. PharmaCyte has contracted with the University of Northern Colorado (UNCO), led by Dr. Richard M. Hyslop, to conduct the research related to PharmaCyte's medical Cannabis program. UNCO has obtained all of the necessary approvals and has now received research Cannabis to enable it to advance PharmaCyte's program.
Industrial Hemp Operations Expansion Continues To Solidify Itself As An Agricultural Commodity As Reports Show Sales North Of $500Mil Annually
PR Newswire Europe - Tue Aug 23, 7:31AM CDT
CORAL SPRINGS, Florida, August 23, 2016 /PRNewswire/ --
Dr. Mark L. Rabe Presents PharmaCyte Biotech's Ongoing Research at Cannabis Cancer Forum
GlobeNewswire - Tue Aug 02, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that on Saturday, July 30, 2016, PharmaCyte's Medical and Scientific Advisory Board member Mark L. Rabe, MD, delivered a presentation entitled "Medical Cannabis for Cancer" as part of a "Cannabis for Cancer Forum" in San Diego.
PharmaCyte Biotech Releases Shareholder Call Playback Information
GlobeNewswire - Fri Jul 29, 8:01AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that an audio recording of the company's shareholder call, which was held on July 28, 2016, by Chief Executive Officer Kenneth L. Waggoner is now available for playback.
PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media.
PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016.
PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research."
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.77 (-0.26)
PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb.
PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel.
PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016.
PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology.
PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.
PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.
JNJ: 118.25 (-0.38)
PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.
PharmaCyte's CEO Discusses Development of its Pancreatic Cancer Therapy
GlobeNewswire - Thu Sep 15, 8:15AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today addressed shareholders on the development of PharmaCyte's therapy for advanced pancreatic cancer. PharmaCyte Biotech Reports on Progress in Its Medical Cannabis Program
GlobeNewswire - Thu Sep 01, 8:35AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today provided an update on its program for developing treatments for serious brain cancers that involve constituents of the Cannabis plant. These Cannabis-based cancer therapies, like PharmaCyte's pancreatic cancer therapy, will involve the use of its Cell-in-a-Box technology. The cancer "prodrug" that will be activated (converted to their cancer-killing forms) by the cells inside the Cell-in-a-Box capsules are constituents of the Cannabis plant known as cannabinoids. PharmaCyte has contracted with the University of Northern Colorado (UNCO), led by Dr. Richard M. Hyslop, to conduct the research related to PharmaCyte's medical Cannabis program. UNCO has obtained all of the necessary approvals and has now received research Cannabis to enable it to advance PharmaCyte's program. Industrial Hemp Operations Expansion Continues To Solidify Itself As An Agricultural Commodity As Reports Show Sales North Of $500Mil Annually
PR Newswire Europe - Tue Aug 23, 7:31AM CDT
CORAL SPRINGS, Florida, August 23, 2016 /PRNewswire/ --
Dr. Mark L. Rabe Presents PharmaCyte Biotech's Ongoing Research at Cannabis Cancer Forum
GlobeNewswire - Tue Aug 02, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that on Saturday, July 30, 2016, PharmaCyte's Medical and Scientific Advisory Board member Mark L. Rabe, MD, delivered a presentation entitled "Medical Cannabis for Cancer" as part of a "Cannabis for Cancer Forum" in San Diego. PharmaCyte Biotech Releases Shareholder Call Playback Information
GlobeNewswire - Fri Jul 29, 8:01AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that an audio recording of the company's shareholder call, which was held on July 28, 2016, by Chief Executive Officer Kenneth L. Waggoner is now available for playback. PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media. PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016. PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research." OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.77 (-0.26)
PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb. PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016. PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology. PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.
PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor. JNJ: 118.25 (-0.38)
PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance. 
(0)
(0)Scroll down for more posts ▼